Faculty

Peter Leary

Adjunct Associate Professor, Epidemiology
Associate Professor, Medicine - Pulmonary, Critical Care and Sleep Medicine

206-685-2484
learyp@uw.edu

Education

PhD Epidemiology, University of Washington, 2018
Master Epidemiology, University of Washington, 2013
MD Medicine (MD), Johns Hopkins University, 2005

Contact

206-685-2484
learyp@uw.edu

University of Washington Medicine
UW Medical Center, BB-1245 Box 356522
Seattle, WA 98195
WA

Bio

Peter Leary is the Director of the Pulmonary Vascular Disease program, a board-certified pulmonologist, and an Associate Professor of Medicine in the Division of Pulmonary, Critical Care, and Sleep Medicine. His research is focused on identifying and targeting mechanisms that contribute to pulmonary hypertension and heart failure.

 

Research Interests

His research interests include heart failure, right ventricular adaptation, pulmonary vascular disease and epidemiology.

Recent Publications (PubMed)

Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study.
(2022 Jan)
Pulm Circ 12(1): e12020
Emmons-Bell S, Johnson C, Boon-Dooley A, Corris PA, Leary PJ, Rich S, Yacoub M, Roth GA

Endothelial-derived von Willebrand factor accelerates fibrin clotting within engineered microvessels.
(2022 Jul)
J Thromb Haemost 20(7): 1627-1637
Rayner SG, Scholl Z, Mandrycky CJ, Chen J, LaValley KN, Leary PJ, Altemeier WA, Liles WC, Chung DW, López JA, Fu H, Zheng Y

Histamine H2 Receptor Antagonists and Heart Failure Risk in Postmenopausal Women: The Women's Health Initiative.
(2022 Mar)
J Am Heart Assoc 11(5): e024270
Larson SR, Vasbinder AL, Reding KW, Leary PJ, Branch KR, Shadyab AH, Johnson KC, Haring B, Wallace R, Manson JE, Anderson G, Cheng RK

Association of soluble Flt-1 with heart failure and cardiac morphology: The MESA angiogenesis study.
(2022 May)
J Heart Lung Transplant 41(5): 619-625
Berardi C, Bluemke DA, Houston BA, Kolb TM, Lima JA, Pezel T, Tedford RJ, Rayner SG, Cheng RK, Leary PJ

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
(2022 Feb)
JHEP Rep 4(2): 100409
Johnson K, Leary PJ, Govaere O, Barter MJ, Charlton SH, Cockell SJ, Tiniakos D, Zatorska M, Bedossa P, Brosnan MJ, Cobbold JF, Ekstedt M, Aithal GP, Clément K, Schattenberg JM, Boursier J, Ratziu V, Bugianesi E, Anstee QM, Daly AK, LITMUS Consortium Investigators§., LITMUS Consortium Investigators.

Show complete publication list

In the News

No news articles at this time.